A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

Gynecologic Oncology

Volumn 62, Issue 2, 1996, Pages 181-191

  Kohn, Elise C ^a   Sarosy, Gisele A ^a   Davis, Patricia ^a   Christian, Michaele ^a   Link, Charles E ^a   Ognibene, Frederick P ^b   Sindelar, William F ^c   Jacob, Joan ^a   Steinberg, Seth M ^d   Premkumar, Ahalya ^e   Reed, Eddie ^a  

^a Clinical Pharmacology Branch   (United States)

^b Critical Care Medicine Department   (United States)

^c Surgery Branch   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CA 125 ANTIGEN; CIMETIDINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; NARCOTIC AGENT; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; HISTOLOGY; HUMAN; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHARMACEUTICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0030221059     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0213     Document Type: Article

References (56)

1. 1. Young, R. C., Perez, C. A., and Hoskins, W. J. Cancer of the ovary, in Cancer: Principles and practice of oncology (V. T. DeVita, S. Hellman, and S. A. Rosenberg, Eds.), Lippincott, Philadelphia, 4th ed., pp. 1226-1263 (1993).
2. 2. van der Burg, M. E. L., can Lent, M., Kobierska, A., Colombo, M., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N. Engl. J. Med. 332, 675-677 (1993).
3. 3. Reed, E., Kohn, E. C., Sarosy, G., Dabholkar, M., Davis, P., Jacob, J., and Maher, M. Paclitaxel (Taxol), cisplatin and cyclophosphamide in human ovarian cancer: Molecular rationale and early clinical results, Semin. Oncol. 22, 90-96 (1995).
4. 4. Rothenberg, M. C., Ozols, R. F., Young, R. C., Glatstein, E. J., Steinberg, S. M., and Reed, E. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer, J. Clin. Oncol. 10, 727-734 (1992).
5. 5. Sarosy, G. A., Kohn, E. C., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., and Reed, E. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J. Clin. Oncol. 10, 1165-1170 (1992).
6. 6. McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesly, H., and Clarke-Pearson, D. L. A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer, Proc. ASCO 11, 226 (1992).
7. 7. Levin, L., Simon, R., and Hryniuk, W. M. Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis, J. Natl. Cancer Inst. 85, 1732-1742 (1993).
8. 8. Levin, L., and Hyrniuk, W. M. Dose intensity analysis of chemotherapy regimens in ovarian cancer, J. Clin. Oncol. 5, 756-767 (1987).
9. 9. McGuire, W. P., Rowinsky, E. K., Rosensheim, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: A unique antineoplastic agent wit significant activity in advanced ovarian epithelial neoplasms, Ann. Int. Med. 111, 273-279 (1989).
10. 10. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol), N. Engl. J. Med. 332, 1004-1014 (1995).
11. 11. Einzig, A. I., Wiernik, P. H., Sasloff, J., Runowica, F. D., and Goldberg, G. L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma, J. Clin. Oncol. 10, 1748-1753 (1992).
12. 12. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., and Buser, K. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion, J. Clin. Oncol. 12, 2654-2666 (1994).
13. 13. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., Cunnion, R. E., and Reed, E. Dose intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer, J. Natl. Cancer Inst. 86, 18-24 (1994).
14. 14. Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., and Barrett, R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy, J. Clin. Oncol. 12, 1748-1753 (1994).
15. 15. Trimble, E. L., Adams, J. D., Vena, D., Hawkins, M. J., Friedman, M. A., Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., Hayn, R., et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103, J. Clin. Oncol. 11, 2405-2410 (1993).
16. 16. Kohn, E. C., and Reed, E. Controversies in the treatment of advanced ovarian cancer, NIH Catalyst, 17-22 (1994).
17. 17. Sarosy, G., and Reed, E. Taxol dose intensification and its clinical implications, J. Natl. Med. Assoc. 85, 427-431 (1993).
18. 18. Ozols, R. F. Chemotherapeutic dose intensity in ovarian cancer, Adv. Oncol. 11, 24-29 (1995).
19. 19. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., and Sartorius, S. Sequences of taxol and cisplatin: a phase I and pharmacologic study, J. Clin. Oncol. 9, 1692-1703 (1991).
20. 20. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
21. 21. McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., and Woodward, J. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group Study, J. Clin. Oncol. 13, 1589-1599 (1995).
22. 22. Decker, D. G., Fleming, T. R., and Malkasian, G. D. Cyclophosphamide plus cis-platinum in combination: Treatment program for stage III or IV ovarian carcinoma, Obstet. Gynecol. 60, 481 (1982).
23. 23. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer, Lancet 2, 353-359 (1987).
24. 24. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia, Italy. Long-term results of a randomized trial comparing cisplatin with cisplatin and Cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer, Gynecol. Oncol. 45, 115-117 (1992).
25. 25. Parker, R. J., Dabholkar, M. D., Lee, K. B., Bostick-Bruton, F., and Reed, E. Taxol effects on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells, Monogr. Natl. Cancer Inst. 15, 83-88 (1993).
26. 26. Bicher, A., Kohn, E. C., Sarosy, G., Davis, P., Adamo, D. O., Jacob, J., Christian, M., and Reed, E. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor, Anti-Cancer Drugs 4, 141-148 (1993).
27. 27. Link, C. J., Bicher, A., Kohn, E. C., Christian, M. C., Davis, P. A., Adamo, D. O., Reed, E., and Sarosy, G. A. Flexible G-CSF dosing in ovarian cancer patients who receive dose intense Taxol therapy, Blood 83, 1188-1192 (1994).
28. 28. Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., and Donehower, R. C. Cardiac disturbances during the administration of Taxol, J. Clin. Oncol. 9, 1704-1712 (1991).
29. 29. Weiss, R. B. Hypersensitivity reactions, Semin. Oncol. 19, 458-477 (1992).
30. 30. Jonckheere, A. R. A distribution-free K-sample test against ordered alternatives, Biometrika 41, 133-145 (1954).
31. 31. Kaplan, E., and Meier, P. Non-parametric estimation from incomplete observations, J. Am. Stat. Assoc. 53, 457-481 (1958).
32. 32. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chem. Rep. 50, 163-170 (1966).
33. 33. White, P. F., Merino, M. J., and Barwick, K. W. Serous surface papillary carcinoma of the ovary: A clinical, pathologic, ultrastructural, and immunohistochemical study of 11 cases, Pathol. Annu. 20, 403-418 (1985).
34. 34. Lippman, S. M., Alberts, D. S., Slymen, D. J., Weiner, S., Aristizabal, S. A., Luditch, A., Davis, J. R., and Surwit, E. A. Second-look laparotomy in epithelial ovarian carcinoma, Cancer 61, 2571-2577 (1988).
35. 35. Neijt, J. P., ten Bokkel Huinink, W. W., and van der Burg, M. E., van Oosterom, A. T., Willemse, P. H., Vermerken, J. B., and van Lindert, A. C. Long-term survival in ovarian cancer: Mature data from the Netherlands Joint Study Group for ovarian cancer, Eur. J. Cancer 27, 1367-1372(1991).
36. 36. Omura, G. A., Brady, M. F., Homesley, H. D., Yordan, E., Major, F. J., Buchsbaum, H. J., and Park, R. C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience, J. Clin. Oncol. 9, 1138-1150 (1991).
37. 37. Reed, E., Janik, J., Bookman, M. A., Rothenberg, M., Smith, J., Young, R. C., Ozols, R. F., VanderMolen, L., Kohn, E., and Jacob, J. L., Cornelison, T. L. High dose carboplatin and rhGM-CSF in advanced stage recurrent ovarian cancer, J. Clin. Oncol. 11, 2118-2126 (1993).
38. 38. Griffiths, C. T. H. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma: Symposium on ovarian cancer, Natl. Cancer Inst. Mongr. 42, 1010-1014 (1975).
39. 39. Edmonson, J. H., McCormack, G. W., Fleming, T. R., Cullinan, S. A., Krook, J. E., Malkasian, G. D., Podratz, K. C., Mailliard, J. A., Jefferies, J. A., Barlow, J. F., and Windschitl, H. E. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas, Cancer Treat. Rep. 69, 1243-1248 (1985).
40. 40. Young, R., Chabner, B., and Hubbard, S. Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy, N. Engl. J. Med. 299, 1261 (1978).
41. 41. Kaye, S. B., Lewis, C. R., Paul, J., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Cassidy, J., Davis, J. A., Reed, N. S., Crawford, S. M., MacLean, A., Swapp, G. A., Sarkar, T. K., Kennedy, J. H., and Symonds, R. P. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer, Lancet 340, 329-333 (1992).
42. 42. Conte, P. F., Bruzzone, M., Carnino, F., et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: A randomized trial in stage III-IV epithelial ovarian carcinoma, J. Clin. Oncol. 9, 658-663 (1991).
43. 43. Swenerton, K., Jeffrey, J., Stuart, G., Roy, M., Krepart, G., Carmichael, J., Drouin, P., Stanimir, R., O'Connell, G., MacLan, G., Kirk, M. E., Canetta, R., Koski, B., Shelley, W., Zee, B., and Pater, J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol. 10, 718-726 (1992).
44. 44. Alberts, D. S., Green, S., Hannigan, E. V., O'Toole, R., Stock-Novack, D., Anderson, P., Surwit, E. A., Malvlya, V. K., Nahhas, W. A., and Jolles, C. J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer, J. Clin. Oncol. 10, 706-717 (1992).
45. 45. Schiff, P. B., Fant, J., and Horowitz, S. B. Promotion of microtubule assembly in vitro by Taxol, Nature 277, 655-667 (1979).
46. 46. Kumar, N. Taxol induced polymerization of purified tubulin, J. Biol. Chem. 256, 10435-10441 (1981).
47. 47. Long, B. H., and Fairchild, C. R. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase, Cancer Res. 54, 4355-4361 (1994).
48. 48. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations, Proc. Natl. Acad. Sci. USA 90, 9552-9556 (1993).
49. 49. Tishler, R. B., Geard, C. R., Hall, E. J., and Schiff, P. B. Taxol sensitizes human astrocytoma cells to radiation, Cancer Res. 52, 3494-3497 (1992).
50. 50. Cleaver, J. E. It was a very good year for DNA repair, Cell 76, 1-4 (1994).
51. 51. Modrich, P. Mismatch repair, genetic stability, and cancer, Science 266, 1959-1960(1995).
52. 52. Sancar, A. Mechanisms of DNA excision repair, Science 266, 1954-1956 (1995).
53. 53. Gabrilove, J., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M. A., and Clarkson, B. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium, N. Engl. J. Med. 318, 1414-1422 (1988).
54. 54. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., and Davidson, M. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer as compared with cytoxan and cisplatin (CP), Proc. ASCO 14, 275 (1995).
55. 55. Louie, K. G., Ozols, R. F., Myers, C. E., Ostchega, Y., Jenkins, J., Howser, D., and Young, R. C. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma, J. Clin. Oncol. 4, 1579-1585 (1986).
56. 56. Sutton, G. P., Stehman, F. B., Einhorn, L. H., Roth, L. M., Blessing, J. A., and Ehrlich, C. E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma, J. Clin. Oncol. 7, 223-229 (1989).